Multiple Sclerosis (MS) is postulated to be a cell mediated AutoImmune Disease directed against Central Nervous System Myelin components (MBP, PLP).
Our understanding of the disease has been enhanced by a number of factors:
- Advances in our understanding of the Immune System
- Clinical trials which are beginning to identify treatments which can affect MS
- A better understanding of the clinical features of MS
- Advances in MRI imaging of the Brain
Based on the current state of knowledge, this paper proposes a 21 point unifying hypothesis on the Etiology and treatment of the disease.
This hypothesis makes a series of assumptions, many of which are unproven, and is presented as a framework from which to investigate and treat the disease, not as an established Biology.
It is hypothesized that the underlying PathoGenesis of MS is related to an inappropriate class of Immune response.
Against Myelin Antigens favoring ProInflammatory Th1 versus Anti-Inflammatory Th2 or Th3 type responses.
Environmental and Genetic factors predispose toward MS by affecting the class of response and effectiveness of treatment is also related to how it impacts on this common final pathway.
Because of Epitope spreading, there is not one AutoAntigen involved in MS and the Progressive form of MS differs Immunologically from the Relapsing/Remitting form.
Viruses trigger and perpetuate MS, although MS is not related to a persistent Viral infection.
Because MS is a multifactorial disease, there are clinical and perhaps Immunological subtypes of MS and a single type of treatment is unlikely to control the disease in all patients.
Thus, there will be responders and non-responders to each effective therapy and ultimately combination therapy will be required to cure the disease.
